Literature DB >> 23721620

Endovascular treatment of chronic, recurrent headache secondary to chronic cerebral venous sinus thrombosis.

Xin-Bin Guo1, Lai-Jun Song2, Sheng Guan3.   

Abstract

Headache is a clinical diagnosis linked to a number of medical and surgical disorders. A common etiology has not yet been established. It would seem that these cases can be related to some degree of cerebral venous outflow obstruction. We report 2 cases of chronic superior sagittal sinus thrombosis causing isolated intracranial hypertension. The patients were treated with intrasinus thrombolytic therapy.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  Cerebral venous sinus thrombosis; endovascular treatment; headache

Mesh：

Year:  2013        PMID： 23721620     DOI： 10.1016/j.jstrokecerebrovasdis.2013.04.005

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN： 1052-3057            Impact factor:   2.136


  4 in total

1.  Transient ischaemic attack: an exceptional presenting syndrome of a superior sagittal sinus thrombosis.

Authors:  Assunta Scuotto; Raffaele D'Avanzo; Massimo Natale; Michele Rotondo
Journal:  BMJ Case Rep       Date:  2013-11-21

Review 2.  Endovascular treatments for cerebral venous sinus thrombosis.

Authors:  Zhongming Qiu; Hongfei Sang; Qiliang Dai; Gelin Xu
Journal:  J Thromb Thrombolysis       Date:  2015-10       Impact factor: 2.300

Review 3.  New Developments in the Pathophysiology, Workup, and Diagnosis of Dural Venous Sinus Thrombosis (DVST) and a Systematic Review of Endovascular Treatments.

Authors:  Sanjay Konakondla; Clemens M Schirmer; Fengwu Li; Xiaogun Geng; Yuchuan Ding
Journal:  Aging Dis       Date:  2017-04-01       Impact factor: 6.745

4.  Predictors of successful endovascular treatment in severe cerebral venous sinus thrombosis.

Authors:  Xiaoxu Yang; Fang Wu; Yuehong Liu; Jiangang Duan; Ran Meng; Jian Chen; Debiao Li; Zhaoyang Fan; Marc Fisher; Qi Yang; Xunming Ji
Journal:  Ann Clin Transl Neurol       Date:  2019-03-07       Impact factor: 4.511
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.